We discovered that ruxolitinib at clinically relevant free drug concentrations synergized with multiple ERBB1/2/4 inhibitors to kill tumor cells, including those expressing mutated active RAS proteins or lacking the tumor suppressor PTEN. Here, EGFR is linked to neoplasm.